Anisomycin (Synonyms: Flagecidin, NSC 76712, Wuningmeisu C) |
Catalog No.GC11559
One-Click Copy Product Info
|
Anisomycin은 스트렙토마이세스 그리세우스에서 분리된 항생제이기도 하고 JNK 활성화제이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 22862-76-6
Sample solution is provided at 25 µL, 10mM.
Anisomycin은 스트렙토마이세스 그리세우스에서 분리된 항생제이기도 하고 JNK 활성화제이다. Anisomycin은 주로 80S 뢰쇠 소유의 펩타이드 전이효소 활동을 억제하여 단백질 합성을 억제한다. 게다가 Anisomycin은 P38, JNK, ERK1/2 경로를 활성화하여 다양한 세포 유형에서 조기 세포사를 유도하고 이로 인해 암에 대한 유망한 화학요법 약물이 되고 있다[1-4].
Anisomycin (10-100nM; 24시간)은 B16 흑색종 세포에서 농도 의존적인 방식으로 세포 생존성을 낮춘다[5]. Anisomycin (1-80 ng/ml; 24시간)은 P53/P21/P27 신호 경로를 활성화하여 ICBP90의 표현을 줄이고, P-CDK2의 표현을 억제하여 세포를 S 및 G2/M 단계에서 막아 Jurkat T 세포 증식을 억제한다[6]. Anisomycin (31.8 μM)은 반대 RNA NCBP2-AS2의 표현을 변화시켜 OCSCs의 증식, 이동, 혈관 생성을 억제한다[7].
Anisomycin (5 mg/kg; i.p; 3주)은 MD-MBA-231 세포 기반의 유방암 모델에서 혈관 생성을 효과적으로 방해하여 캡일러리 네트워크 형성을 훼손하고 세포 이동, 증식, 생존을 억제한다[8]. Anisomycin (2-200μg/kg; i.p; 30일)은 mdx 쥐의 복막에서 유트로핀 단백질 수준을 상향 조절한다[9].
References：
[1]. Grollman AP. Inhibitors of protein biosynthesis. II. Mode of action of anisomycin. J Biol Chem. 1967 Jul 10;242(13):3226-33. PMID: 6027796.
[2]. Hall SS, Loebenberg D, et,al. Structure-activity relationships of synthetic antibiotic analogues of anisomycin. J Med Chem. 1983 Apr;26(4):469-75. doi: 10.1021/jm00358a003. PMID: 6834379.
[3]. Schmeits PC, Katika MR, et,al. DON shares a similar mode of action as the ribotoxic stress inducer anisomycin while TBTO shares ER stress patterns with the ER stress inducer thapsigargin based on comparative gene expression profiling in Jurkat T cells. Toxicol Lett. 2014 Jan 30;224(3):395-406. doi: 10.1016/j.toxlet.2013.11.005. Epub 2013 Nov 15. PMID: 24247028.
[4]. Slipicevic A, Øy GF, et,al. Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biol Ther. 2013 Feb;14(2):146-54. doi: 10.4161/cbt.22953. Epub 2012 Nov 28. PMID: 23192275; PMCID: PMC3571996.
[5]. Ushijima H, Monzaki R, et,al. Suppressive Effects of Anisomycin on the Proliferation of B16 Mouse Melanoma Cells In Vitro. Anticancer Res. 2021 Dec;41(12):6113-6121. doi: 10.21873/anticanres.15431. PMID: 34848466.
[6]. Yu C, Xing F, et,al. Anisomycin suppresses Jurkat T cell growth by the cell cycle-regulating proteins. Pharmacol Rep. 2013;65(2):435-44. doi: 10.1016/s1734-1140(13)71019-3. PMID: 23744428.
[7]. Ling L, Wen Y, et,al. Anisomycin inhibits the activity of human ovarian cancer stem cells via regulating antisense RNA NCBP2-AS2/MEK/ERK/STAT3 signaling. J Gene Med. 2024 Jan;26(1):e3571. doi: 10.1002/jgm.3571. Epub 2023 Jul 22. PMID: 37483091.
[8]. Yang W, Zhou C, et,al. Anisomycin inhibits angiogenesis, growth, and survival of triple-negative breast cancer through mitochondrial dysfunction, AMPK activation, and mTOR inhibition. Can J Physiol Pharmacol. 2022 Jul 1;100(7):612-620. doi: 10.1139/cjpp-2021-0577. Epub 2022 Jul 19. PMID: 35852219.
[9]. Hadwen J, Farooq F, et,al. Anisomycin Activates Utrophin Upregulation Through a p38 Signaling Pathway. Clin Transl Sci. 2018 Sep;11(5):506-512. doi: 10.1111/cts.12562. Epub 2018 Jun 7. PMID: 29877606; PMCID: PMC6132359.
| 세포 실험 [1]: | |
세포 라인 | B16 세포 |
제조 방법 | 세포는 96웰 미세 판(6×103 세포/웰)에 재배했습니다. 24시간 후 미디엄은 다양한 농도의 Anisomycin을 포함하는 신선한 미디엄으로 변경되었고 추가로 24시간 동안 배양했습니다. |
반응 조건 | 0-100nM; 24시간 동안 |
응용 분야 | 10nM보다 높은 Anisomycin 농도가 농도 의존적인 방식으로 세포 생존성을 저하시켰습니다. |
| 동물 실험 [2]: | |
동물 모형 | 6주령 SCID 쥐 (MD-MBA-231 세포 유방암 모델) |
제조 방법 | 종양 이식 후 1주일째에 치료를 시작했습니다. 5 mg/kg의 Anisomycin이나 100 µL의 PBS를 복강 주사를 통해 투여했습니다. |
제형 | 5 mg/kg; i.p; 3주 동안 |
응용 분야 | Anisomycin은 MDA-MB-231 종양의 생장에 대해 현저하게 억제합니다. |
References: | |
| Cas No. | 22862-76-6 | SDF | |
| Synonyms | Flagecidin, NSC 76712, Wuningmeisu C | ||
| Chemical Name | (2R,3S,4S)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate | ||
| Canonical SMILES | O[C@@H]1[C@H]([C@@H](CC(C=C2)=CC=C2OC)NC1)OC(C)=O | ||
| Formula | C14H19NO4 | M.Wt | 265.31 |
| Solubility | ≥ 26.5mg/mL in DMSO | Storage | Store at -20°C,protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7692 mL | 18.8459 mL | 37.6918 mL |
| 5 mM | 753.8 μL | 3.7692 mL | 7.5384 mL |
| 10 mM | 376.9 μL | 1.8846 mL | 3.7692 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
TIL-35 promoted microglial M2 polarization via suppressing JNK signaling. (A)Western blot was performed to determine protein levels of JNK and p-JNK.
HAPI cells were pre-treated with anisomycin (0.1μM; JNK signaling activator; Glpbio, Montclair, CA, USA).
Arch Biochem Biophys (2020): 108330. PMID: 32156533 IF: 4.01 -
Related Biological Data
TAK1 knockdown improves cell viability and alleviates the inflammation of H/R‑induced Caco‑2 cells. (B) Expression levels of TNF‑α, IL‑6 and IL‑1β in the five groups were determined using reverse transcription‑quan‑titative PCR.
Anisomycin, a type of JNK agonist, was purchased from GlpBio Technology and diluted to 4µM.
Exp Ther Med 23.2 (2022): 1-9. PMID: 35069839 IF: 2.443 -
Related Biological Data
Butorphanol decreases LPS‑induced apoptosis via p38/JNK/ATF2/p53 signaling. (A) Anisomycin increased the number of apoptotic cells.
Cells were pretreated with butorphanol (1, 2 and 4µM; GlpBio Technology) and/or anisomycin (1µM; GlpBio Technology Inc.).
Exp Ther Med 23.3 (2022): 1-9. PMID: 35222706 IF: 2.443 -
Related Biological Data
Knockdown of ANKRD49 downregulates MMP-2/MMP-9 expression of H1703 cells. (G, H) The levels of JNK, p-JNK, p38, p-p38, MMP-2 and MMP-9 in ANKRD49-sh H1703 cells treated with SP600125, SB203580, Anisomycin or DMSO were measured by Western blot. β-Tubulin served as an internal control. Data are expressed as means±standard deviation.
Anisomycin (20µM) (GlpBio, USA), an activator of JNK and p38 MAPK was used to pretreat ANKRD49-sh H1703 cells for 1h.
bioRxiv (2023): 2023-03. PMID: 37964204
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)